Home

Report

Trends in Drug Shortages and ANDA Approvals in the U.S.

Trends in Drug Shortages and ANDA Approvals in the U.S.

IQVIA
Pages 19 Pages

This research brief examines persistent drug shortages in the U.S., particularly affecting generic and injectable medicines. It analyzes the relationship between FDA ANDA approvals and delayed or unlaunched generics, revealing economic and manufacturing barriers that limit market entry. The report highlights supply chain fragility, low pricing incentives, and long launch timelines as key contributors. It concludes with recommendations to strengthen incentives and resilience to improve drug availability.

Join for free to read

You Might Also Like


Drug Shortages in the U.S. 2023
Report Drug Shortages in the U.S. 2023
IQVIA

Using Type 9 NDA Designation to Accelerate Multiple Approvals for Your Drug Product
Case Study Using Type 9 NDA Designation to Accelerate Multiple Approvals…
Certara Clinical Trial Outcomes Databases

Mitigating Drug Shortages: Strategies for Resilient Pharmaceutical Supply Chains
White Paper Mitigating Drug Shortages: Strategies for Resilient…
IQVIA

Ten MedTech Trends to Watch in 2024
Ebook Ten MedTech Trends to Watch in 2024
IQVIA

More from IQVIA


Drug Shortages in the U.S. 2023
Report Drug Shortages in the U.S. 2023
IQVIA

Mitigating Drug Shortages: Strategies for Resilient Pharmaceutical Supply Chains
White Paper Mitigating Drug Shortages: Strategies for Resilient…
IQVIA

Ten MedTech Trends to Watch in 2024
Ebook Ten MedTech Trends to Watch in 2024
IQVIA

Trends in Adult Vaccination in the U.S.
Report Trends in Adult Vaccination in the U.S.
IQVIA
© 2026 Contentree.  All Rights Reserved   |   Privacy and Cookies   |   Legal   |   Do not sell my info